Otolith Labs

Otolith Labs is a medical technology company established in 2015, focusing on the development of noninvasive wearable devices for vestibular disorders. The company was founded by Samuel Owen and Jonathan Akers and is headquartered in Washington, D.C. Owen, the CEO, conceived of the company's core technology following a master's degree in physics from Georgetown University, where he studied acceleration sensors and posited their application to the human vestibular system. His background includes over a decade of work with acoustics and acceleration sensors, which was foundational to the company's patented technology. Initially targeting motion sickness, the company pivoted after discovering its technology's significant potential for treating chronic vertigo, a condition affecting millions with limited treatment options.

The company's flagship product is a prescription wearable headband, currently known as the OtoBand, that utilizes what Otolith Labs calls non-invasive Vestibular Resonance Therapy (nVRT), also referred to as noninvasive Vestibular System Masking (nVSM). This technology works by applying localized, calibrated vibrations to the vestibular system—the sensory organs in the inner ear responsible for balance—through a specialized bone conduction speaker. The goal is to mask disruptive signals from a malfunctioning vestibular system, providing immediate relief from vertigo symptoms without pharmacological intervention. The device is intended to be used by patients to manage acute symptoms, potentially in conjunction with long-term treatments like vestibular therapy.

Otolith Labs operates in the medical device market, targeting patients suffering from chronic vertigo and other vestibular disorders. Its business model centers on obtaining regulatory approval to commercialize its prescription wearable device. In June 2021, the U.S. Food and Drug Administration (FDA) granted the device Breakthrough Device Designation, a status intended to expedite the review of technologies that could provide more effective treatment for debilitating conditions. The company has been actively conducting clinical trials to validate the technology's efficacy, with pilot studies of approximately 100 participants showing that subjects using the device were significantly more likely to report symptom improvement compared to a placebo group. Otolith Labs has successfully raised a total of $33.8 million through multiple funding rounds, including a $20 million Series A in 2022 led by Morningside Ventures and a $3.3 million seed round in 2021 with investors like Mark Cuban's Radical Investments. Keywords: chronic vertigo treatment, vestibular disorders, medical wearable, non-invasive therapy, nVRT, nVSM, balance disorders, Sam Owen, vestibular rehabilitation, medtech, FDA Breakthrough Device, bone conduction, dizziness treatment, motion sickness wearable, OtoBand, Morningside Ventures, Mark Cuban, vestibular stimulation, Halcyon Incubator, medical device, prescription wearable, inner ear technology, acceleration sensors, vestibular system masking